These in vivo data together suggest that pharmacological inhibition of wt-IDH2 could have potential application in AML treatment, and IDH2 inhibitors such as AGI-6780 seem well tolerated in vivo. This evidence concerns the gene IDH2 and acute myeloid leukemia.